Morphine Sulfate
NDC Package 27808-084-02

11-digit billing NDC: 27808008402

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Morphine Sulfate is oral Solution 2 mg/mL is indicated for the management of:adults with pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.pediatric patients 2 years of age and older with pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.Morphine Sulfate Oral Solution 20 mg/mL is indicated for use in opioid-tolerant adult patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.Limitations of Use:Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2)], reserve opioid analgesics, including Morphine Sulfate Oral Solution, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Marketed by Cranbury Pharmaceuticals, Llc, this product is identified by NDC 27808-084 and is authorized under FDA application ANDA203518.

Identification & Billing

NDC Package Code
27808-084-02
Package Description
500 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
27808008402
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Morphine Sulfate
Dosage Form
-
Usage Information
Morphine Sulfate Oral Solution 2 mg/mL is indicated for the management of:adults with pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.pediatric patients 2 years of age and older with pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.Morphine Sulfate Oral Solution 20 mg/mL is indicated for use in opioid-tolerant adult patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate.Limitations of Use:Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions (5.2)], reserve opioid analgesics, including Morphine Sulfate Oral Solution, for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.

Regulatory & Marketing

Labeler Name
Cranbury Pharmaceuticals, Llc
FDA Application #
ANDA203518
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
09-21-2015
End Marketing Date
09-10-2021
Listing Expiration
09-10-2021
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (27808-084). Click a package code to view its specific billing and regulatory data.

1 BOTTLE, UNIT-DOSE in 1 CARTON / 100 mL in 1 BOTTLE, UNIT-DOSE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 27808-084-02 identifies a specific commercial package of 500 ml in 1 bottle of Morphine Sulfate, labeled by Cranbury Pharmaceuticals, Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Cranbury Pharmaceuticals, Llc on September 21, 2015. The current certification is valid through September 10, 2021.

How is this Cranbury Pharmaceuticals, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 27808008402. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
27808-084-02
11-Digit CMS (5-4-2)
27808-0084-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.